Evidence map›Paper›PMID 24047106›Full record

ArticleACS chemical neuroscience2013

The impact of neurochemical mediators on antidepressant effectiveness.

Richard J Metzner

Abstract read
In one paragraph

Article in ACS chemical neuroscience, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.3field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Richard J MetznerDepartment of Psychiatry and Biobehavioral Sciences, Semel Institute for Neuroscience and Human Behavior, University of California at Los Angeles , Los Angeles, California 90095, United States.
University of California, Los Angeles · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Despite marked differences in the psychobiological profiles of depressed patients, clinical research has not supported selection of antidepressant (AD) medications based on neurochemistry. Prescribers have been advised to start all patients on the same class of ADs and then switch or combine them until benefit is achieved. New research may transform this practice. By matching clinical moderators to neurochemical mediators, health professionals may finally be able to overcome the disappointing remission rates associated with initial AD treatments and avoid the progressively worsening results associated with current trial and error approaches.

Indexed as

AgedAntidepressive AgentsCatecholaminesEvidence-Based MedicineFemaleGenetic VariationHumansMaleMiddle AgedMolecular StructureNeurotransmitter AgentsPatient SelectionRandomized Controlled Trials as TopicRemission InductionSelective Serotonin Reuptake InhibitorsSerotoninAntidepressive AgentsCatecholaminesNeurotransmitter AgentsSelective Serotonin Reuptake InhibitorsSerotonin

Identifiers

PMID24047106
PMCPMC3778421
OpenAlexW1971935394

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.